nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ALB—atherosclerosis	0.168	1	CbGaD
Fluoxetine—ALB—Rosuvastatin—atherosclerosis	0.039	0.0704	CbGbCtD
Fluoxetine—CYP2B6—Simvastatin—atherosclerosis	0.037	0.0668	CbGbCtD
Fluoxetine—CYP3A5—Rosuvastatin—atherosclerosis	0.0313	0.0566	CbGbCtD
Fluoxetine—CYP3A5—Simvastatin—atherosclerosis	0.0291	0.0526	CbGbCtD
Fluoxetine—CYP3A5—Pravastatin—atherosclerosis	0.0285	0.0515	CbGbCtD
Fluoxetine—CYP3A5—Lovastatin—atherosclerosis	0.0285	0.0515	CbGbCtD
Fluoxetine—CYP2C19—Rosuvastatin—atherosclerosis	0.0253	0.0456	CbGbCtD
Fluoxetine—CYP2C19—Simvastatin—atherosclerosis	0.0235	0.0424	CbGbCtD
Fluoxetine—CYP2C19—Lovastatin—atherosclerosis	0.023	0.0415	CbGbCtD
Fluoxetine—CYP2D6—Niacin—atherosclerosis	0.0226	0.0408	CbGbCtD
Fluoxetine—CYP2C9—Rosuvastatin—atherosclerosis	0.021	0.0379	CbGbCtD
Fluoxetine—ABCB1—Ezetimibe—atherosclerosis	0.0204	0.0368	CbGbCtD
Fluoxetine—CYP2C9—Simvastatin—atherosclerosis	0.0195	0.0353	CbGbCtD
Fluoxetine—CYP2C9—Lovastatin—atherosclerosis	0.0191	0.0345	CbGbCtD
Fluoxetine—CYP2C9—Pravastatin—atherosclerosis	0.0191	0.0345	CbGbCtD
Fluoxetine—ABCB1—Simvastatin—atherosclerosis	0.019	0.0342	CbGbCtD
Fluoxetine—ABCB1—Pravastatin—atherosclerosis	0.0185	0.0335	CbGbCtD
Fluoxetine—ABCB1—Lovastatin—atherosclerosis	0.0185	0.0335	CbGbCtD
Fluoxetine—CYP2D6—Simvastatin—atherosclerosis	0.0179	0.0323	CbGbCtD
Fluoxetine—CYP2D6—Pravastatin—atherosclerosis	0.0175	0.0316	CbGbCtD
Fluoxetine—CYP2D6—Lovastatin—atherosclerosis	0.0175	0.0316	CbGbCtD
Fluoxetine—CYP3A4—Rosuvastatin—atherosclerosis	0.0122	0.0221	CbGbCtD
Fluoxetine—CYP3A4—Ezetimibe—atherosclerosis	0.0122	0.0221	CbGbCtD
Fluoxetine—CYP3A4—Simvastatin—atherosclerosis	0.0114	0.0205	CbGbCtD
Fluoxetine—CYP3A4—Pravastatin—atherosclerosis	0.0111	0.0201	CbGbCtD
Fluoxetine—CYP3A4—Lovastatin—atherosclerosis	0.0111	0.0201	CbGbCtD
Fluoxetine—Cinacalcet—CASR—atherosclerosis	0.00385	0.778	CrCbGaD
Fluoxetine—HTR2A—arteriole—atherosclerosis	0.000925	0.215	CbGeAlD
Fluoxetine—Bromodiphenhydramine—HRH1—atherosclerosis	0.000756	0.153	CrCbGaD
Fluoxetine—HTR2A—vein—atherosclerosis	0.000551	0.128	CbGeAlD
Fluoxetine—HTR2A—hindlimb—atherosclerosis	0.000366	0.0851	CbGeAlD
Fluoxetine—Orphenadrine—HRH1—atherosclerosis	0.000343	0.0693	CrCbGaD
Fluoxetine—HTR2A—appendage—atherosclerosis	0.000314	0.073	CbGeAlD
Fluoxetine—HTR2A—artery—atherosclerosis	0.000225	0.0522	CbGeAlD
Fluoxetine—Flatulence—Simvastatin—atherosclerosis	0.000222	0.00119	CcSEcCtD
Fluoxetine—Tinnitus—Niacin—atherosclerosis	0.000221	0.00119	CcSEcCtD
Fluoxetine—Erythema multiforme—Pravastatin—atherosclerosis	0.000221	0.00119	CcSEcCtD
Fluoxetine—Dysgeusia—Simvastatin—atherosclerosis	0.00022	0.00118	CcSEcCtD
Fluoxetine—Angioedema—Lovastatin—atherosclerosis	0.00022	0.00118	CcSEcCtD
Fluoxetine—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000219	0.00118	CcSEcCtD
Fluoxetine—Anaemia—Ezetimibe—atherosclerosis	0.000218	0.00117	CcSEcCtD
Fluoxetine—Tinnitus—Pravastatin—atherosclerosis	0.000218	0.00117	CcSEcCtD
Fluoxetine—Malaise—Lovastatin—atherosclerosis	0.000217	0.00117	CcSEcCtD
Fluoxetine—Muscle spasms—Simvastatin—atherosclerosis	0.000216	0.00116	CcSEcCtD
Fluoxetine—Vertigo—Lovastatin—atherosclerosis	0.000216	0.00116	CcSEcCtD
Fluoxetine—Angioedema—Ezetimibe—atherosclerosis	0.000216	0.00116	CcSEcCtD
Fluoxetine—Leukopenia—Lovastatin—atherosclerosis	0.000215	0.00116	CcSEcCtD
Fluoxetine—Chills—Niacin—atherosclerosis	0.000213	0.00114	CcSEcCtD
Fluoxetine—Malaise—Ezetimibe—atherosclerosis	0.000213	0.00114	CcSEcCtD
Fluoxetine—Arrhythmia—Niacin—atherosclerosis	0.000212	0.00114	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000211	0.00113	CcSEcCtD
Fluoxetine—Tremor—Simvastatin—atherosclerosis	0.000211	0.00113	CcSEcCtD
Fluoxetine—Alopecia—Niacin—atherosclerosis	0.00021	0.00113	CcSEcCtD
Fluoxetine—Chills—Pravastatin—atherosclerosis	0.00021	0.00113	CcSEcCtD
Fluoxetine—Insomnia—Rosuvastatin—atherosclerosis	0.000209	0.00113	CcSEcCtD
Fluoxetine—Ill-defined disorder—Simvastatin—atherosclerosis	0.000209	0.00112	CcSEcCtD
Fluoxetine—Arrhythmia—Pravastatin—atherosclerosis	0.000209	0.00112	CcSEcCtD
Fluoxetine—Palpitations—Ezetimibe—atherosclerosis	0.000208	0.00112	CcSEcCtD
Fluoxetine—Paraesthesia—Rosuvastatin—atherosclerosis	0.000208	0.00112	CcSEcCtD
Fluoxetine—Anaemia—Simvastatin—atherosclerosis	0.000208	0.00112	CcSEcCtD
Fluoxetine—Malnutrition—Niacin—atherosclerosis	0.000207	0.00111	CcSEcCtD
Fluoxetine—Alopecia—Pravastatin—atherosclerosis	0.000206	0.00111	CcSEcCtD
Fluoxetine—Cough—Ezetimibe—atherosclerosis	0.000206	0.00111	CcSEcCtD
Fluoxetine—Angioedema—Simvastatin—atherosclerosis	0.000206	0.00111	CcSEcCtD
Fluoxetine—Myalgia—Lovastatin—atherosclerosis	0.000205	0.0011	CcSEcCtD
Fluoxetine—Arthralgia—Lovastatin—atherosclerosis	0.000205	0.0011	CcSEcCtD
Fluoxetine—Chest pain—Lovastatin—atherosclerosis	0.000205	0.0011	CcSEcCtD
Fluoxetine—Anxiety—Lovastatin—atherosclerosis	0.000204	0.0011	CcSEcCtD
Fluoxetine—Dyspepsia—Rosuvastatin—atherosclerosis	0.000204	0.0011	CcSEcCtD
Fluoxetine—Hypertension—Ezetimibe—atherosclerosis	0.000204	0.00109	CcSEcCtD
Fluoxetine—Flatulence—Niacin—atherosclerosis	0.000204	0.00109	CcSEcCtD
Fluoxetine—Malaise—Simvastatin—atherosclerosis	0.000203	0.00109	CcSEcCtD
Fluoxetine—Tension—Niacin—atherosclerosis	0.000203	0.00109	CcSEcCtD
Fluoxetine—Discomfort—Lovastatin—atherosclerosis	0.000202	0.00109	CcSEcCtD
Fluoxetine—Vertigo—Simvastatin—atherosclerosis	0.000202	0.00109	CcSEcCtD
Fluoxetine—Leukopenia—Simvastatin—atherosclerosis	0.000201	0.00108	CcSEcCtD
Fluoxetine—Arthralgia—Ezetimibe—atherosclerosis	0.000201	0.00108	CcSEcCtD
Fluoxetine—Myalgia—Ezetimibe—atherosclerosis	0.000201	0.00108	CcSEcCtD
Fluoxetine—Chest pain—Ezetimibe—atherosclerosis	0.000201	0.00108	CcSEcCtD
Fluoxetine—Nervousness—Niacin—atherosclerosis	0.000201	0.00108	CcSEcCtD
Fluoxetine—Flatulence—Pravastatin—atherosclerosis	0.0002	0.00108	CcSEcCtD
Fluoxetine—Dry mouth—Lovastatin—atherosclerosis	0.0002	0.00108	CcSEcCtD
Fluoxetine—Tension—Pravastatin—atherosclerosis	0.0002	0.00107	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000199	0.00107	CcSEcCtD
Fluoxetine—Dysgeusia—Pravastatin—atherosclerosis	0.000199	0.00107	CcSEcCtD
Fluoxetine—Muscle spasms—Niacin—atherosclerosis	0.000199	0.00107	CcSEcCtD
Fluoxetine—Discomfort—Ezetimibe—atherosclerosis	0.000198	0.00107	CcSEcCtD
Fluoxetine—Pain—Rosuvastatin—atherosclerosis	0.000198	0.00106	CcSEcCtD
Fluoxetine—Constipation—Rosuvastatin—atherosclerosis	0.000198	0.00106	CcSEcCtD
Fluoxetine—Confusional state—Lovastatin—atherosclerosis	0.000198	0.00106	CcSEcCtD
Fluoxetine—Nervousness—Pravastatin—atherosclerosis	0.000198	0.00106	CcSEcCtD
Fluoxetine—Dry mouth—Ezetimibe—atherosclerosis	0.000196	0.00106	CcSEcCtD
Fluoxetine—Anaphylactic shock—Lovastatin—atherosclerosis	0.000196	0.00106	CcSEcCtD
Fluoxetine—Muscle spasms—Pravastatin—atherosclerosis	0.000196	0.00105	CcSEcCtD
Fluoxetine—Infection—Lovastatin—atherosclerosis	0.000195	0.00105	CcSEcCtD
Fluoxetine—Confusional state—Ezetimibe—atherosclerosis	0.000194	0.00104	CcSEcCtD
Fluoxetine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000192	0.00104	CcSEcCtD
Fluoxetine—Thrombocytopenia—Lovastatin—atherosclerosis	0.000192	0.00103	CcSEcCtD
Fluoxetine—Chest pain—Simvastatin—atherosclerosis	0.000191	0.00103	CcSEcCtD
Fluoxetine—Arthralgia—Simvastatin—atherosclerosis	0.000191	0.00103	CcSEcCtD
Fluoxetine—Myalgia—Simvastatin—atherosclerosis	0.000191	0.00103	CcSEcCtD
Fluoxetine—Infection—Ezetimibe—atherosclerosis	0.000191	0.00103	CcSEcCtD
Fluoxetine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000191	0.00103	CcSEcCtD
Fluoxetine—Anxiety—Simvastatin—atherosclerosis	0.000191	0.00103	CcSEcCtD
Fluoxetine—Tremor—Pravastatin—atherosclerosis	0.000191	0.00102	CcSEcCtD
Fluoxetine—HTR2A—endothelium—atherosclerosis	0.00019	0.0441	CbGeAlD
Fluoxetine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000189	0.00102	CcSEcCtD
Fluoxetine—Discomfort—Simvastatin—atherosclerosis	0.000189	0.00102	CcSEcCtD
Fluoxetine—Angioedema—Niacin—atherosclerosis	0.000189	0.00101	CcSEcCtD
Fluoxetine—Ill-defined disorder—Pravastatin—atherosclerosis	0.000189	0.00101	CcSEcCtD
Fluoxetine—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000188	0.00101	CcSEcCtD
Fluoxetine—Anaemia—Pravastatin—atherosclerosis	0.000188	0.00101	CcSEcCtD
Fluoxetine—Anorexia—Lovastatin—atherosclerosis	0.000187	0.00101	CcSEcCtD
Fluoxetine—Skin disorder—Ezetimibe—atherosclerosis	0.000187	0.00101	CcSEcCtD
Fluoxetine—Angioedema—Pravastatin—atherosclerosis	0.000186	0.000999	CcSEcCtD
Fluoxetine—Vertigo—Niacin—atherosclerosis	0.000186	0.000998	CcSEcCtD
Fluoxetine—Syncope—Niacin—atherosclerosis	0.000185	0.000996	CcSEcCtD
Fluoxetine—Confusional state—Simvastatin—atherosclerosis	0.000185	0.000995	CcSEcCtD
Fluoxetine—Leukopenia—Niacin—atherosclerosis	0.000185	0.000994	CcSEcCtD
Fluoxetine—Urticaria—Rosuvastatin—atherosclerosis	0.000184	0.000989	CcSEcCtD
Fluoxetine—Anaphylactic shock—Simvastatin—atherosclerosis	0.000184	0.000987	CcSEcCtD
Fluoxetine—Malaise—Pravastatin—atherosclerosis	0.000183	0.000986	CcSEcCtD
Fluoxetine—Abdominal pain—Rosuvastatin—atherosclerosis	0.000183	0.000984	CcSEcCtD
Fluoxetine—Vertigo—Pravastatin—atherosclerosis	0.000183	0.000982	CcSEcCtD
Fluoxetine—Palpitations—Niacin—atherosclerosis	0.000183	0.000981	CcSEcCtD
Fluoxetine—Infection—Simvastatin—atherosclerosis	0.000182	0.000981	CcSEcCtD
Fluoxetine—Leukopenia—Pravastatin—atherosclerosis	0.000182	0.000979	CcSEcCtD
Fluoxetine—Loss of consciousness—Niacin—atherosclerosis	0.000182	0.000976	CcSEcCtD
Fluoxetine—Cough—Niacin—atherosclerosis	0.00018	0.000969	CcSEcCtD
Fluoxetine—Thrombocytopenia—Simvastatin—atherosclerosis	0.00018	0.000966	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000179	0.000961	CcSEcCtD
Fluoxetine—Insomnia—Lovastatin—atherosclerosis	0.000178	0.000954	CcSEcCtD
Fluoxetine—Cough—Pravastatin—atherosclerosis	0.000177	0.000954	CcSEcCtD
Fluoxetine—Paraesthesia—Lovastatin—atherosclerosis	0.000176	0.000948	CcSEcCtD
Fluoxetine—Myalgia—Niacin—atherosclerosis	0.000176	0.000945	CcSEcCtD
Fluoxetine—Arthralgia—Niacin—atherosclerosis	0.000176	0.000945	CcSEcCtD
Fluoxetine—Hypertension—Pravastatin—atherosclerosis	0.000176	0.000944	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000175	0.000943	CcSEcCtD
Fluoxetine—HTR2A—blood vessel—atherosclerosis	0.000175	0.0406	CbGeAlD
Fluoxetine—Anorexia—Simvastatin—atherosclerosis	0.000175	0.000941	CcSEcCtD
Fluoxetine—Dyspnoea—Lovastatin—atherosclerosis	0.000175	0.000941	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000175	0.000939	CcSEcCtD
Fluoxetine—Insomnia—Ezetimibe—atherosclerosis	0.000174	0.000936	CcSEcCtD
Fluoxetine—Myalgia—Pravastatin—atherosclerosis	0.000173	0.000931	CcSEcCtD
Fluoxetine—Arthralgia—Pravastatin—atherosclerosis	0.000173	0.000931	CcSEcCtD
Fluoxetine—Chest pain—Pravastatin—atherosclerosis	0.000173	0.000931	CcSEcCtD
Fluoxetine—Paraesthesia—Ezetimibe—atherosclerosis	0.000173	0.000929	CcSEcCtD
Fluoxetine—Dyspepsia—Lovastatin—atherosclerosis	0.000173	0.000929	CcSEcCtD
Fluoxetine—Anxiety—Pravastatin—atherosclerosis	0.000173	0.000928	CcSEcCtD
Fluoxetine—Dry mouth—Niacin—atherosclerosis	0.000172	0.000925	CcSEcCtD
Fluoxetine—Dyspnoea—Ezetimibe—atherosclerosis	0.000172	0.000923	CcSEcCtD
Fluoxetine—Discomfort—Pravastatin—atherosclerosis	0.000171	0.00092	CcSEcCtD
Fluoxetine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000171	0.000917	CcSEcCtD
Fluoxetine—Decreased appetite—Lovastatin—atherosclerosis	0.000171	0.000917	CcSEcCtD
Fluoxetine—Dyspepsia—Ezetimibe—atherosclerosis	0.000169	0.000911	CcSEcCtD
Fluoxetine—Fatigue—Lovastatin—atherosclerosis	0.000169	0.00091	CcSEcCtD
Fluoxetine—Anaphylactic shock—Niacin—atherosclerosis	0.000169	0.000906	CcSEcCtD
Fluoxetine—Constipation—Lovastatin—atherosclerosis	0.000168	0.000902	CcSEcCtD
Fluoxetine—Pain—Lovastatin—atherosclerosis	0.000168	0.000902	CcSEcCtD
Fluoxetine—Confusional state—Pravastatin—atherosclerosis	0.000167	0.0009	CcSEcCtD
Fluoxetine—Decreased appetite—Ezetimibe—atherosclerosis	0.000167	0.0009	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000167	0.000899	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000166	0.000894	CcSEcCtD
Fluoxetine—Asthenia—Rosuvastatin—atherosclerosis	0.000166	0.000893	CcSEcCtD
Fluoxetine—Insomnia—Simvastatin—atherosclerosis	0.000166	0.000893	CcSEcCtD
Fluoxetine—Anaphylactic shock—Pravastatin—atherosclerosis	0.000166	0.000892	CcSEcCtD
Fluoxetine—Fatigue—Ezetimibe—atherosclerosis	0.000166	0.000892	CcSEcCtD
Fluoxetine—Shock—Niacin—atherosclerosis	0.000166	0.000892	CcSEcCtD
Fluoxetine—Infection—Pravastatin—atherosclerosis	0.000165	0.000887	CcSEcCtD
Fluoxetine—Paraesthesia—Simvastatin—atherosclerosis	0.000165	0.000886	CcSEcCtD
Fluoxetine—Pain—Ezetimibe—atherosclerosis	0.000165	0.000885	CcSEcCtD
Fluoxetine—Constipation—Ezetimibe—atherosclerosis	0.000165	0.000885	CcSEcCtD
Fluoxetine—Tachycardia—Niacin—atherosclerosis	0.000165	0.000885	CcSEcCtD
Fluoxetine—Pruritus—Rosuvastatin—atherosclerosis	0.000164	0.000881	CcSEcCtD
Fluoxetine—Skin disorder—Niacin—atherosclerosis	0.000164	0.00088	CcSEcCtD
Fluoxetine—Dyspnoea—Simvastatin—atherosclerosis	0.000164	0.00088	CcSEcCtD
Fluoxetine—Hyperhidrosis—Niacin—atherosclerosis	0.000163	0.000876	CcSEcCtD
Fluoxetine—Thrombocytopenia—Pravastatin—atherosclerosis	0.000162	0.000874	CcSEcCtD
Fluoxetine—Feeling abnormal—Lovastatin—atherosclerosis	0.000162	0.00087	CcSEcCtD
Fluoxetine—Dyspepsia—Simvastatin—atherosclerosis	0.000162	0.000869	CcSEcCtD
Fluoxetine—Anorexia—Niacin—atherosclerosis	0.000161	0.000864	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00016	0.000863	CcSEcCtD
Fluoxetine—Hyperhidrosis—Pravastatin—atherosclerosis	0.00016	0.000863	CcSEcCtD
Fluoxetine—Decreased appetite—Simvastatin—atherosclerosis	0.00016	0.000858	CcSEcCtD
Fluoxetine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000159	0.000853	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000158	0.000852	CcSEcCtD
Fluoxetine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000158	0.000852	CcSEcCtD
Fluoxetine—Fatigue—Simvastatin—atherosclerosis	0.000158	0.000851	CcSEcCtD
Fluoxetine—Anorexia—Pravastatin—atherosclerosis	0.000158	0.000851	CcSEcCtD
Fluoxetine—Hypotension—Niacin—atherosclerosis	0.000158	0.000847	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000157	0.000846	CcSEcCtD
Fluoxetine—Pain—Simvastatin—atherosclerosis	0.000157	0.000844	CcSEcCtD
Fluoxetine—Constipation—Simvastatin—atherosclerosis	0.000157	0.000844	CcSEcCtD
Fluoxetine—Urticaria—Lovastatin—atherosclerosis	0.000156	0.000838	CcSEcCtD
Fluoxetine—Abdominal pain—Lovastatin—atherosclerosis	0.000155	0.000834	CcSEcCtD
Fluoxetine—Body temperature increased—Lovastatin—atherosclerosis	0.000155	0.000834	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000154	0.000826	CcSEcCtD
Fluoxetine—Dizziness—Rosuvastatin—atherosclerosis	0.000153	0.000823	CcSEcCtD
Fluoxetine—Urticaria—Ezetimibe—atherosclerosis	0.000153	0.000822	CcSEcCtD
Fluoxetine—Insomnia—Niacin—atherosclerosis	0.000152	0.00082	CcSEcCtD
Fluoxetine—Abdominal pain—Ezetimibe—atherosclerosis	0.000152	0.000818	CcSEcCtD
Fluoxetine—Body temperature increased—Ezetimibe—atherosclerosis	0.000152	0.000818	CcSEcCtD
Fluoxetine—Paraesthesia—Niacin—atherosclerosis	0.000151	0.000814	CcSEcCtD
Fluoxetine—Feeling abnormal—Simvastatin—atherosclerosis	0.000151	0.000813	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000151	0.000813	CcSEcCtD
Fluoxetine—Dyspnoea—Niacin—atherosclerosis	0.00015	0.000808	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00015	0.000807	CcSEcCtD
Fluoxetine—Insomnia—Pravastatin—atherosclerosis	0.00015	0.000807	CcSEcCtD
Fluoxetine—Somnolence—Niacin—atherosclerosis	0.00015	0.000806	CcSEcCtD
Fluoxetine—Paraesthesia—Pravastatin—atherosclerosis	0.000149	0.000801	CcSEcCtD
Fluoxetine—Dyspepsia—Niacin—atherosclerosis	0.000148	0.000798	CcSEcCtD
Fluoxetine—Dyspnoea—Pravastatin—atherosclerosis	0.000148	0.000796	CcSEcCtD
Fluoxetine—Decreased appetite—Niacin—atherosclerosis	0.000147	0.000788	CcSEcCtD
Fluoxetine—Dyspepsia—Pravastatin—atherosclerosis	0.000146	0.000786	CcSEcCtD
Fluoxetine—Rash—Rosuvastatin—atherosclerosis	0.000146	0.000785	CcSEcCtD
Fluoxetine—Dermatitis—Rosuvastatin—atherosclerosis	0.000146	0.000784	CcSEcCtD
Fluoxetine—Urticaria—Simvastatin—atherosclerosis	0.000146	0.000784	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000146	0.000782	CcSEcCtD
Fluoxetine—Abdominal pain—Simvastatin—atherosclerosis	0.000145	0.00078	CcSEcCtD
Fluoxetine—Body temperature increased—Simvastatin—atherosclerosis	0.000145	0.00078	CcSEcCtD
Fluoxetine—Headache—Rosuvastatin—atherosclerosis	0.000145	0.00078	CcSEcCtD
Fluoxetine—Hypersensitivity—Lovastatin—atherosclerosis	0.000145	0.000777	CcSEcCtD
Fluoxetine—Decreased appetite—Pravastatin—atherosclerosis	0.000144	0.000776	CcSEcCtD
Fluoxetine—Pain—Niacin—atherosclerosis	0.000144	0.000775	CcSEcCtD
Fluoxetine—Fatigue—Pravastatin—atherosclerosis	0.000143	0.000769	CcSEcCtD
Fluoxetine—Pain—Pravastatin—atherosclerosis	0.000142	0.000763	CcSEcCtD
Fluoxetine—Constipation—Pravastatin—atherosclerosis	0.000142	0.000763	CcSEcCtD
Fluoxetine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000142	0.000763	CcSEcCtD
Fluoxetine—Asthenia—Lovastatin—atherosclerosis	0.000141	0.000757	CcSEcCtD
Fluoxetine—Pruritus—Lovastatin—atherosclerosis	0.000139	0.000747	CcSEcCtD
Fluoxetine—Asthenia—Ezetimibe—atherosclerosis	0.000138	0.000743	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Niacin—atherosclerosis	0.000138	0.000741	CcSEcCtD
Fluoxetine—Nausea—Rosuvastatin—atherosclerosis	0.000138	0.00074	CcSEcCtD
Fluoxetine—Feeling abnormal—Pravastatin—atherosclerosis	0.000137	0.000735	CcSEcCtD
Fluoxetine—Pruritus—Ezetimibe—atherosclerosis	0.000136	0.000732	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000136	0.00073	CcSEcCtD
Fluoxetine—Hypersensitivity—Simvastatin—atherosclerosis	0.000135	0.000727	CcSEcCtD
Fluoxetine—Diarrhoea—Lovastatin—atherosclerosis	0.000134	0.000722	CcSEcCtD
Fluoxetine—Urticaria—Niacin—atherosclerosis	0.000134	0.00072	CcSEcCtD
Fluoxetine—Abdominal pain—Niacin—atherosclerosis	0.000133	0.000716	CcSEcCtD
Fluoxetine—Body temperature increased—Niacin—atherosclerosis	0.000133	0.000716	CcSEcCtD
Fluoxetine—Urticaria—Pravastatin—atherosclerosis	0.000132	0.000709	CcSEcCtD
Fluoxetine—Asthenia—Simvastatin—atherosclerosis	0.000132	0.000708	CcSEcCtD
Fluoxetine—Diarrhoea—Ezetimibe—atherosclerosis	0.000132	0.000708	CcSEcCtD
Fluoxetine—Abdominal pain—Pravastatin—atherosclerosis	0.000131	0.000705	CcSEcCtD
Fluoxetine—Body temperature increased—Pravastatin—atherosclerosis	0.000131	0.000705	CcSEcCtD
Fluoxetine—Pruritus—Simvastatin—atherosclerosis	0.00013	0.000698	CcSEcCtD
Fluoxetine—Dizziness—Lovastatin—atherosclerosis	0.00013	0.000698	CcSEcCtD
Fluoxetine—SIGMAR1—adipose tissue—atherosclerosis	0.000129	0.03	CbGeAlD
Fluoxetine—Dizziness—Ezetimibe—atherosclerosis	0.000127	0.000684	CcSEcCtD
Fluoxetine—Diarrhoea—Simvastatin—atherosclerosis	0.000126	0.000675	CcSEcCtD
Fluoxetine—Vomiting—Lovastatin—atherosclerosis	0.000125	0.000671	CcSEcCtD
Fluoxetine—Hypersensitivity—Niacin—atherosclerosis	0.000124	0.000668	CcSEcCtD
Fluoxetine—Rash—Lovastatin—atherosclerosis	0.000124	0.000665	CcSEcCtD
Fluoxetine—Dermatitis—Lovastatin—atherosclerosis	0.000124	0.000665	CcSEcCtD
Fluoxetine—Headache—Lovastatin—atherosclerosis	0.000123	0.000661	CcSEcCtD
Fluoxetine—Vomiting—Ezetimibe—atherosclerosis	0.000122	0.000658	CcSEcCtD
Fluoxetine—Hypersensitivity—Pravastatin—atherosclerosis	0.000122	0.000657	CcSEcCtD
Fluoxetine—Dizziness—Simvastatin—atherosclerosis	0.000121	0.000653	CcSEcCtD
Fluoxetine—Rash—Ezetimibe—atherosclerosis	0.000121	0.000653	CcSEcCtD
Fluoxetine—Dermatitis—Ezetimibe—atherosclerosis	0.000121	0.000652	CcSEcCtD
Fluoxetine—Asthenia—Niacin—atherosclerosis	0.000121	0.00065	CcSEcCtD
Fluoxetine—Headache—Ezetimibe—atherosclerosis	0.000121	0.000648	CcSEcCtD
Fluoxetine—Pruritus—Niacin—atherosclerosis	0.000119	0.000641	CcSEcCtD
Fluoxetine—Asthenia—Pravastatin—atherosclerosis	0.000119	0.00064	CcSEcCtD
Fluoxetine—Pruritus—Pravastatin—atherosclerosis	0.000117	0.000631	CcSEcCtD
Fluoxetine—Vomiting—Simvastatin—atherosclerosis	0.000117	0.000628	CcSEcCtD
Fluoxetine—Nausea—Lovastatin—atherosclerosis	0.000117	0.000627	CcSEcCtD
Fluoxetine—Rash—Simvastatin—atherosclerosis	0.000116	0.000622	CcSEcCtD
Fluoxetine—Dermatitis—Simvastatin—atherosclerosis	0.000116	0.000622	CcSEcCtD
Fluoxetine—Diarrhoea—Niacin—atherosclerosis	0.000115	0.00062	CcSEcCtD
Fluoxetine—Headache—Simvastatin—atherosclerosis	0.000115	0.000618	CcSEcCtD
Fluoxetine—ABCB1—blood vessel—atherosclerosis	0.000115	0.0266	CbGeAlD
Fluoxetine—Nausea—Ezetimibe—atherosclerosis	0.000114	0.000615	CcSEcCtD
Fluoxetine—Diarrhoea—Pravastatin—atherosclerosis	0.000114	0.000611	CcSEcCtD
Fluoxetine—Dizziness—Niacin—atherosclerosis	0.000111	0.000599	CcSEcCtD
Fluoxetine—Dizziness—Pravastatin—atherosclerosis	0.00011	0.00059	CcSEcCtD
Fluoxetine—Nausea—Simvastatin—atherosclerosis	0.000109	0.000586	CcSEcCtD
Fluoxetine—Vomiting—Niacin—atherosclerosis	0.000107	0.000576	CcSEcCtD
Fluoxetine—ORM1—liver—atherosclerosis	0.000107	0.0249	CbGeAlD
Fluoxetine—Rash—Niacin—atherosclerosis	0.000106	0.000571	CcSEcCtD
Fluoxetine—Dermatitis—Niacin—atherosclerosis	0.000106	0.000571	CcSEcCtD
Fluoxetine—Headache—Niacin—atherosclerosis	0.000106	0.000568	CcSEcCtD
Fluoxetine—Vomiting—Pravastatin—atherosclerosis	0.000106	0.000567	CcSEcCtD
Fluoxetine—Rash—Pravastatin—atherosclerosis	0.000105	0.000563	CcSEcCtD
Fluoxetine—Dermatitis—Pravastatin—atherosclerosis	0.000105	0.000562	CcSEcCtD
Fluoxetine—Headache—Pravastatin—atherosclerosis	0.000104	0.000559	CcSEcCtD
Fluoxetine—Nausea—Niacin—atherosclerosis	0.0001	0.000538	CcSEcCtD
Fluoxetine—Nausea—Pravastatin—atherosclerosis	9.86e-05	0.00053	CcSEcCtD
Fluoxetine—CYP2B6—cardiovascular system—atherosclerosis	9.57e-05	0.0222	CbGeAlD
Fluoxetine—CYP2C9—cardiovascular system—atherosclerosis	9.48e-05	0.022	CbGeAlD
Fluoxetine—ALB—liver—atherosclerosis	9.39e-05	0.0218	CbGeAlD
Fluoxetine—SIGMAR1—liver—atherosclerosis	9.06e-05	0.021	CbGeAlD
Fluoxetine—HTR2A—connective tissue—atherosclerosis	8.97e-05	0.0208	CbGeAlD
Fluoxetine—CYP3A5—adipose tissue—atherosclerosis	8.49e-05	0.0197	CbGeAlD
Fluoxetine—HTR2A—cardiovascular system—atherosclerosis	7.81e-05	0.0181	CbGeAlD
Fluoxetine—CYP2C19—liver—atherosclerosis	7.56e-05	0.0176	CbGeAlD
Fluoxetine—CYP1A2—liver—atherosclerosis	6.17e-05	0.0143	CbGeAlD
Fluoxetine—CYP3A5—liver—atherosclerosis	5.96e-05	0.0138	CbGeAlD
Fluoxetine—CYP2B6—liver—atherosclerosis	5.92e-05	0.0137	CbGeAlD
Fluoxetine—CYP2C9—liver—atherosclerosis	5.86e-05	0.0136	CbGeAlD
Fluoxetine—ABCB1—cardiovascular system—atherosclerosis	5.12e-05	0.0119	CbGeAlD
Fluoxetine—HTR2A—liver—atherosclerosis	4.83e-05	0.0112	CbGeAlD
Fluoxetine—ABCB1—adipose tissue—atherosclerosis	4.51e-05	0.0105	CbGeAlD
Fluoxetine—CYP3A4—liver—atherosclerosis	4.47e-05	0.0104	CbGeAlD
Fluoxetine—CYP2D6—liver—atherosclerosis	4.4e-05	0.0102	CbGeAlD
Fluoxetine—ABCB1—liver—atherosclerosis	3.16e-05	0.00735	CbGeAlD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	6.9e-06	8.3e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—LIPC—atherosclerosis	6.9e-06	8.3e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ABCA1—atherosclerosis	6.88e-06	8.28e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—APOC3—atherosclerosis	6.85e-06	8.25e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GPX1—atherosclerosis	6.82e-06	8.2e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PRKCG—atherosclerosis	6.81e-06	8.2e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—LDLR—atherosclerosis	6.81e-06	8.2e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CD36—atherosclerosis	6.79e-06	8.17e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—LEP—atherosclerosis	6.76e-06	8.14e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APOE—atherosclerosis	6.76e-06	8.14e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ABCA1—atherosclerosis	6.72e-06	8.09e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—VEGFA—atherosclerosis	6.71e-06	8.08e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CAV1—atherosclerosis	6.7e-06	8.07e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—LPA—atherosclerosis	6.7e-06	8.06e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APOA1—atherosclerosis	6.69e-06	8.05e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CETP—atherosclerosis	6.65e-06	8.01e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CD36—atherosclerosis	6.64e-06	7.99e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SPP1—atherosclerosis	6.64e-06	7.99e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CXCL8—atherosclerosis	6.61e-06	7.95e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—HMOX1—atherosclerosis	6.58e-06	7.92e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—BGN—atherosclerosis	6.49e-06	7.81e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ESR1—atherosclerosis	6.46e-06	7.77e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—MTHFR—atherosclerosis	6.44e-06	7.75e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—APOA5—atherosclerosis	6.42e-06	7.73e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—F2—atherosclerosis	6.38e-06	7.68e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—SCARB1—atherosclerosis	6.37e-06	7.67e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	6.35e-06	7.64e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MAPK3—atherosclerosis	6.35e-06	7.64e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ABCA1—atherosclerosis	6.33e-06	7.62e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PPARA—atherosclerosis	6.31e-06	7.6e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—APOB—atherosclerosis	6.3e-06	7.58e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—MTHFR—atherosclerosis	6.29e-06	7.57e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ABCA1—atherosclerosis	6.28e-06	7.55e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	6.2e-06	7.47e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	6.18e-06	7.44e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PPARA—atherosclerosis	6.17e-06	7.43e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TGFB1—atherosclerosis	6.16e-06	7.42e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PDGFB—atherosclerosis	6.14e-06	7.39e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTM1—atherosclerosis	6.13e-06	7.38e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—AGT—atherosclerosis	6.12e-06	7.36e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CG—atherosclerosis	6.1e-06	7.35e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—HMGCR—atherosclerosis	6.02e-06	7.24e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—LPL—atherosclerosis	6.02e-06	7.24e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AGT—atherosclerosis	6e-06	7.21e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—APOE—atherosclerosis	5.99e-06	7.21e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—AGT—atherosclerosis	5.98e-06	7.19e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALOX5—atherosclerosis	5.97e-06	7.19e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CAV1—atherosclerosis	5.94e-06	7.14e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—APOA1—atherosclerosis	5.92e-06	7.13e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—HMOX1—atherosclerosis	5.91e-06	7.11e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—LEP—atherosclerosis	5.87e-06	7.07e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APOE—atherosclerosis	5.87e-06	7.07e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GPX1—atherosclerosis	5.87e-06	7.06e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—APOE—atherosclerosis	5.86e-06	7.05e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—MAPK3—atherosclerosis	5.85e-06	7.04e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CAV1—atherosclerosis	5.82e-06	7e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APOA1—atherosclerosis	5.81e-06	6.99e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CAV1—atherosclerosis	5.8e-06	6.98e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—APOA1—atherosclerosis	5.79e-06	6.97e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—INS—atherosclerosis	5.78e-06	6.95e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—HMOX1—atherosclerosis	5.76e-06	6.94e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CD36—atherosclerosis	5.72e-06	6.88e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCL2—atherosclerosis	5.69e-06	6.84e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—APOB—atherosclerosis	5.66e-06	6.81e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ESR1—atherosclerosis	5.61e-06	6.75e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IGF1—atherosclerosis	5.59e-06	6.73e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—F2—atherosclerosis	5.54e-06	6.67e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—APOB—atherosclerosis	5.52e-06	6.64e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTM1—atherosclerosis	5.5e-06	6.62e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—HMOX1—atherosclerosis	5.43e-06	6.54e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	5.43e-06	6.53e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—MTHFR—atherosclerosis	5.42e-06	6.52e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CG—atherosclerosis	5.41e-06	6.51e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—LPL—atherosclerosis	5.4e-06	6.5e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—HMOX1—atherosclerosis	5.39e-06	6.48e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTM1—atherosclerosis	5.37e-06	6.46e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ABCA1—atherosclerosis	5.36e-06	6.45e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NAMPT—atherosclerosis	5.36e-06	6.45e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—LIPC—atherosclerosis	5.32e-06	6.41e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PPARA—atherosclerosis	5.32e-06	6.4e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	5.31e-06	6.39e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	5.3e-06	6.38e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—APOC3—atherosclerosis	5.29e-06	6.37e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CG—atherosclerosis	5.29e-06	6.36e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—LPL—atherosclerosis	5.27e-06	6.34e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GPX1—atherosclerosis	5.27e-06	6.34e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—LDLR—atherosclerosis	5.26e-06	6.33e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PPARG—atherosclerosis	5.22e-06	6.28e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—APOB—atherosclerosis	5.2e-06	6.26e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—APOB—atherosclerosis	5.16e-06	6.21e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—AGT—atherosclerosis	5.15e-06	6.19e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GPX1—atherosclerosis	5.14e-06	6.19e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CETP—atherosclerosis	5.14e-06	6.18e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CD36—atherosclerosis	5.13e-06	6.18e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—INS—atherosclerosis	5.12e-06	6.16e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PPARG—atherosclerosis	5.1e-06	6.14e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	5.08e-06	6.11e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOS3—atherosclerosis	5.07e-06	6.1e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTM1—atherosclerosis	5.06e-06	6.09e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—APOE—atherosclerosis	5.04e-06	6.07e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—INS—atherosclerosis	5.02e-06	6.04e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTM1—atherosclerosis	5.02e-06	6.04e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CD36—atherosclerosis	5.01e-06	6.03e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—INS—atherosclerosis	5e-06	6.02e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CAV1—atherosclerosis	5e-06	6.01e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—APOA1—atherosclerosis	4.99e-06	6e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—LPL—atherosclerosis	4.97e-06	5.98e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCL2—atherosclerosis	4.94e-06	5.94e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—LPL—atherosclerosis	4.93e-06	5.93e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SCARB1—atherosclerosis	4.92e-06	5.92e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—MTHFR—atherosclerosis	4.86e-06	5.85e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IGF1—atherosclerosis	4.85e-06	5.84e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GPX1—atherosclerosis	4.85e-06	5.83e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GPX1—atherosclerosis	4.81e-06	5.78e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PPARA—atherosclerosis	4.77e-06	5.74e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—MTHFR—atherosclerosis	4.75e-06	5.71e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CD36—atherosclerosis	4.72e-06	5.68e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ALB—atherosclerosis	4.69e-06	5.65e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CD36—atherosclerosis	4.68e-06	5.63e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PPARA—atherosclerosis	4.66e-06	5.6e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—HMGCR—atherosclerosis	4.64e-06	5.59e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—AGT—atherosclerosis	4.62e-06	5.56e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	4.61e-06	5.55e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—HMOX1—atherosclerosis	4.6e-06	5.54e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ALB—atherosclerosis	4.59e-06	5.52e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CG—atherosclerosis	4.55e-06	5.48e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—APOE—atherosclerosis	4.53e-06	5.45e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—AGT—atherosclerosis	4.51e-06	5.43e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	4.5e-06	5.41e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—NOS3—atherosclerosis	4.49e-06	5.4e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CAV1—atherosclerosis	4.49e-06	5.4e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—APOA1—atherosclerosis	4.48e-06	5.39e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—MTHFR—atherosclerosis	4.47e-06	5.38e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—MTHFR—atherosclerosis	4.43e-06	5.34e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—APOE—atherosclerosis	4.42e-06	5.32e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—APOB—atherosclerosis	4.41e-06	5.3e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOS3—atherosclerosis	4.4e-06	5.3e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PPARG—atherosclerosis	4.39e-06	5.29e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PPARA—atherosclerosis	4.39e-06	5.28e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—NOS3—atherosclerosis	4.39e-06	5.28e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CAV1—atherosclerosis	4.38e-06	5.27e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—APOA1—atherosclerosis	4.37e-06	5.26e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PPARA—atherosclerosis	4.35e-06	5.24e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	4.34e-06	5.23e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—INS—atherosclerosis	4.31e-06	5.19e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTM1—atherosclerosis	4.29e-06	5.16e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—AKT1—atherosclerosis	4.28e-06	5.16e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL6—atherosclerosis	4.27e-06	5.14e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AGT—atherosclerosis	4.25e-06	5.11e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AGT—atherosclerosis	4.21e-06	5.07e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—LPL—atherosclerosis	4.21e-06	5.06e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—APOE—atherosclerosis	4.16e-06	5.01e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ABCA1—atherosclerosis	4.14e-06	4.98e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—APOE—atherosclerosis	4.13e-06	4.97e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CAV1—atherosclerosis	4.13e-06	4.97e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—APOA1—atherosclerosis	4.12e-06	4.95e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GPX1—atherosclerosis	4.11e-06	4.94e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTGS2—atherosclerosis	4.11e-06	4.94e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CAV1—atherosclerosis	4.09e-06	4.92e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CG—atherosclerosis	4.09e-06	4.92e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—APOA1—atherosclerosis	4.08e-06	4.91e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MMP9—atherosclerosis	4.07e-06	4.89e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	4.02e-06	4.84e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTGS2—atherosclerosis	4.01e-06	4.83e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CD36—atherosclerosis	4e-06	4.81e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CG—atherosclerosis	3.99e-06	4.8e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	3.95e-06	4.76e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PPARG—atherosclerosis	3.94e-06	4.75e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	3.94e-06	4.75e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	3.9e-06	4.7e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—INS—atherosclerosis	3.87e-06	4.65e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PPARG—atherosclerosis	3.85e-06	4.63e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—MTHFR—atherosclerosis	3.79e-06	4.56e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—NOS3—atherosclerosis	3.78e-06	4.55e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—INS—atherosclerosis	3.78e-06	4.54e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	3.77e-06	4.54e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	3.76e-06	4.52e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CG—atherosclerosis	3.73e-06	4.48e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PPARA—atherosclerosis	3.72e-06	4.47e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL6—atherosclerosis	3.71e-06	4.47e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	3.65e-06	4.39e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PPARG—atherosclerosis	3.63e-06	4.37e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—atherosclerosis	3.62e-06	4.35e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AGT—atherosclerosis	3.6e-06	4.33e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PPARG—atherosclerosis	3.6e-06	4.33e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—INS—atherosclerosis	3.56e-06	4.28e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—HMOX1—atherosclerosis	3.55e-06	4.27e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ALB—atherosclerosis	3.55e-06	4.27e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MMP9—atherosclerosis	3.53e-06	4.25e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—APOE—atherosclerosis	3.53e-06	4.25e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—INS—atherosclerosis	3.53e-06	4.24e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CAV1—atherosclerosis	3.5e-06	4.21e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	3.49e-06	4.2e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—APOA1—atherosclerosis	3.49e-06	4.2e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ALB—atherosclerosis	3.46e-06	4.17e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS2—atherosclerosis	3.46e-06	4.16e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	3.45e-06	4.16e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	3.43e-06	4.13e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	3.42e-06	4.12e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—APOB—atherosclerosis	3.4e-06	4.09e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—NOS3—atherosclerosis	3.39e-06	4.08e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	3.35e-06	4.03e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—NOS3—atherosclerosis	3.31e-06	3.98e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.31e-06	3.98e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ALB—atherosclerosis	3.26e-06	3.93e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—LPL—atherosclerosis	3.25e-06	3.91e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ALB—atherosclerosis	3.23e-06	3.89e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CG—atherosclerosis	3.18e-06	3.83e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	3.17e-06	3.82e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GPX1—atherosclerosis	3.17e-06	3.81e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—atherosclerosis	3.14e-06	3.78e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—NOS3—atherosclerosis	3.12e-06	3.75e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS2—atherosclerosis	3.1e-06	3.73e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—NOS3—atherosclerosis	3.09e-06	3.72e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CD36—atherosclerosis	3.09e-06	3.71e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PPARG—atherosclerosis	3.07e-06	3.7e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS2—atherosclerosis	3.03e-06	3.64e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—INS—atherosclerosis	3.01e-06	3.63e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	3e-06	3.61e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.92e-06	3.52e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	2.91e-06	3.5e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PPARA—atherosclerosis	2.87e-06	3.45e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS2—atherosclerosis	2.85e-06	3.43e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS2—atherosclerosis	2.83e-06	3.4e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AGT—atherosclerosis	2.78e-06	3.34e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALB—atherosclerosis	2.76e-06	3.33e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—APOE—atherosclerosis	2.72e-06	3.28e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CAV1—atherosclerosis	2.7e-06	3.25e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—APOA1—atherosclerosis	2.69e-06	3.24e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NOS3—atherosclerosis	2.64e-06	3.18e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6—atherosclerosis	2.53e-06	3.04e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.46e-06	2.96e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS2—atherosclerosis	2.42e-06	2.91e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PPARG—atherosclerosis	2.37e-06	2.85e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—AKT1—atherosclerosis	2.33e-06	2.8e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—INS—atherosclerosis	2.33e-06	2.8e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6—atherosclerosis	2.19e-06	2.64e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALB—atherosclerosis	2.13e-06	2.57e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—AKT1—atherosclerosis	2.06e-06	2.48e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NOS3—atherosclerosis	2.04e-06	2.45e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AKT1—atherosclerosis	2.02e-06	2.43e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—AKT1—atherosclerosis	2.02e-06	2.43e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.87e-06	2.25e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—AKT1—atherosclerosis	1.74e-06	2.09e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—AKT1—atherosclerosis	1.56e-06	1.88e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—AKT1—atherosclerosis	1.52e-06	1.83e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AKT1—atherosclerosis	1.43e-06	1.73e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AKT1—atherosclerosis	1.42e-06	1.71e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AKT1—atherosclerosis	1.22e-06	1.46e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AKT1—atherosclerosis	9.38e-07	1.13e-05	CbGpPWpGaD
